Guggenheim analyst Vamil Divan lowered the firm’s price target on Calliditas Therapeutics to $18 from $21 and keeps a Neutral rating on the shares. Calliditas reported Q2 results with Tarpeyo sales that were below expectations and the company lowered their 2023 net Tarpeyo US sales guidance to $100M-$120M, the analyst tells investors in a research note. The firm remains cautious on the product’s longer-term outlook given increased competition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CALT:
- Calliditas Therapeutics announces FDA acceptance of Tarpeyo sNDA
- Calliditas Therapeutics’ NefIgArd phase 3 trial results published in The Lancet
- Calliditas Therapeutics reports publication of NefIgArd Study data in The Lancet
- CALT Earnings this Week: How Will it Perform?
- Calliditas Therapeutics announces interim data from setanaxib trial
